StrataGraft, a regenerative tissue developed by Madison-based Stratatech, has received priority review from the Food and Drug Administration, according to a release from the company. The review by the FDA will determine whether to approve StrataGraft, a tissue product using human cells derived from discarded foreskins after circumcision, by Feb. 2. Stratatech employs 100 staff and is located in the west side University Research Park.Â
Related story: FDA application submitted for Stratatech tissue to treat burns
